Gary Patou - Dec 8, 2021 Form 4 Insider Report for Xenon Pharmaceuticals Inc. (XENE)

Role: Director
Signature: /s/ Cassandra Robinson, Attorney-in-fact
Stock symbol: XENE
Transactions as of: Dec 8, 2021
Transactions value $: $7,549
Form type: 4
Date filed: 12/10/2021, 03:20 PM
Previous filing: Jun 4, 2021
Next filing: Jun 29, 2022

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	XENE	Common Shares	Options Exercise	$7.55K	+2.06K	+8.73%	$3.67^*	25.6K	Dec 8, 2021	Direct	F1
holding	XENE	Common Shares						12.5K	Dec 8, 2021	See Note	F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	XENE	Stock Option (Right to Buy)	Options Exercise	$0	-2.06K	-100%	$0.00^*	0	Dec 8, 2021	Common Shares	2.06K	$3.67	Direct	F1, F3

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	The exercise price was converted from $3.74 CAD using the closing rate of exchange of the Bank of Canada on the date of grant. The actual exercise price is the Canadian dollar amount regardless of the exchange rate on the date of exercise.
F2	By Gary & Karen Barbara Patou TTEE Patou Family Trust FBO Gary Patou Karen Barbara Patou.
F3	1/3 of the shares subject to the Option vested on January 1, 2013 (the "2012 Vesting Commencement Date") and thereafter the remaining 2/3 of the shares subject to the Option vest each monthly anniversary of the 2012 Vesting Commencement Date over the following 2 years.